Possess and maintain in effect all licences required to dispense prescription medication in the state of utah.
Proach. Fisher exact test was used to evaluate the between-treatment-group differences in the proportion of subjects with certain adverse experiences, with the primary focus being upper gastrointestinal adverse experiences. RESULTS Women randomized to the two treatment groups had similar baseline characteristics in terms of age, years since menopause, body mass index, dietary calcium intake, prior vertebral fracture, history of upper gastrointestinal disease, and prior nonsteroidal antiinflammatory drugs or aspirin use Table 1 ; . Although women with radiologic fractures of the lumbar spine were excluded at screening based on local review of spine radiographs, small, comparable proportions of women enrolled in the two treatment groups 5.5% and 3.6% in the 5-mg daily and 35-mg once-weekly groups, respectively ; had baseline vertebral fractures as determined by central review of spine radiographs. These subjects were not discontinued from the study. At baseline, women in the two treatment groups had similar bone mineral density values at the lumbar spine and total hip, as well as similar rates of bone turnover, as indicated by levels of bone resorption and formation markers Table 1 ; . Of the 723 subjects randomized, 83.7% 82.5% and 84.8% in the alendronate 5-mg daily and 35-mg once-weekly groups, respectively ; were included in the completers' analysis of the primary end point. Reasons for exclusion from the completers' analysis include discontinuation owing to clinical adverse experiences, lost to follow-up, withdrew consent, and protocol deviation. There was no apparent betweentreatment-group difference in the proportion of discontinued patients in each category. The primary end point was the change in lumbar spine bone mineral density from baseline at month 12. As shown in Figure 1 and Table 2, treatment with alendronate 35 mg once weekly and 5 mg daily over 12 months resulted in significant percentage increases from baseline in lumbar spine bone mineral density 2.9% and 3.2%, respectively, at month 12 ; . The between-treatment-group difference in the percent change at month 12 90% CI ; was 0.3% 0.6, 0.1 ; , with the 90% CI falling well within the prespecified bounds of 1.0%, indicating that the two treatment regimens are equivalent with respect to the primary end point Figure 2 ; . Significant increases in bone mineral density from baseline were also observed at the total hip, femoral neck, trochanter, and total body in both treatment groups Figure 1 and Table 2 ; . There was no meaningful between-treatmentgroup difference in the percent change at month 12 at. Type: Leg elevation Dose: Both legs elevated at 15 degrees Timing: From premedication including during surgery ; until 1 week post-op. Ambulation allowed but patients discouraged from sitting. Additional noncomparative prophylaxis: Not reported.

2005 common drugs and their uses, for example, alendronate half life.

Discount Drugs Also, the bioavailability of 2800 or 5600 iu of cholecalciferol is similar when administered as fosamax plus d™ or individually without alendronate. In our "enlightened" society the terms stigma and mentally ill seem to go hand in hand. Stigma, according to Webster's Pocket Dictionary, is a sign of disgrace. This is no surprise to those who have studied history and especially the history of mental illness. If you are a student of history you probably know that the ancient Greeks and Romans were more enlightened and sometimes even more tolerant and compassionate of those with mental illness than we are today. There are many references in both Greek and Roman medical literature stating from their rudimentary medical research that many mental illnesses seemed to be based in biological phenomenon. Since most mental illnesses i.e. Bipolar Disorder, Schizophrenia, Major and Clinical Depression, Obsessive Compulsive Disorder, and many forms of Anxiety Disorders ; are now believed to be caused by chemical imbalances in the brain and the nervous system and since human beings have basically remained the same since creation it is no wonder that mental illness has been a problem for individuals and society at large since the beginning of time. For those who "don't measure up" in society today, there is a pervasive thinking that these individuals are inferior or deficient in some way. Thirty or forty years ago, and even to some extent today, persons with cancer were stigmatized out of fear and misunderstanding. I would like to say that this is exactly what is still happening to the "mentally ill today." The fear that causes people to stigmatize cancer patients stems mainly from ignorance, bias, and the need for a scapegoat for many of our problems. This same fear causes people to stigmatize those of us who have a mental illness. In my opinion, the compassionate, altruistic, philanthropic, and for a time financially practical, rounding up of mental patients to "incarcerate" them in the "total institution" to "care for them" created a sub-class of citizens who have been mocked, derided, mistreated and stigmatized. I believe the movement to Community Based Treatment and Recovery Model versus the Medical Model of Treatment may be the next best step to putting an end to stigma and discrimination and really assisting those of us who have severe and persistent mental illness to take back our place in society and amlodipine. CPT only 2004 American Medical Association. All Rights Reserved. 167.

Alendronate ingredients In the said alendronate fasamax attorneys below fasamax generic the medicines, the informations fasamax attorneys below the scenarios st of fasamax attorneys the ayahuasca and amoxycillin. Ache inhibitor with an antioxidant such as tocopherol or gingko bilboa, estrogen or a nonsteroidal antiinflammatory have yet to be established. Lortab 7.5 500 Tablet CIII Lortab 10 500 Tablet CIII MS Contin Tablet CII MS Contin Tablet CII and clavulanate.

Methodology Health Information Designs, Inc. HID ; has developed criteria for the evaluation. Recipients have to meet all criteria listed below in order to be selected for review and evaluation. Osteoporosis and Oral Corticosteroid Criteria 1. Beneficiary must have a diagnosis at any time in their history of osteoporosis. The following ICD-9 diagnoses will be used: 733.00 Osteoporosis Unspecified 733.01 Senile Osteoporosis 733.02 Idiopathic Osteoporosis 733.03 Disuse Osteoporosis 733.09 Other Osteoporosis 733.90 Osteopenia 2. Beneficiaries must have NOT received any of the following drugs for the treatment of osteoporosis during the most recent 90 days: Alendronnate Fosamax ; Calcitonin Miacalcin ; Estrogen replacement therapy excluding oral contraceptives ; Etidronate Didronel Raloxifene Evista ; Risedronate Actonel ; Teriparatide Forteo ; Ibandronate Boniva ; 3. The beneficiary must have received a 30-day supply of an oral corticosteroid drug during the most recent 90 days. For the targeted intervention, the most recent 90-day period will be reviewed. Claims data will be evaluated against the criteria and cases will be identified for review. Beneficiary drug history profiles, along with any available diagnosis data, will be reviewed by an HID clinical pharmacist. A complete drug history profile, along with any available diagnosis data, will be included with an intervention letter. The drug history profile will contain the following alert message: The profile history indicates that the patient has a diagnosis of osteoporosis and is receiving corticosteroid therapy. Corticosteroid therapy in patients with osteoporosis may increase the risk of fractures due to decreased bone density. Vanpen ® is another commercially available vehicle which has been used for delivery of lipophilic drugs and ampicillin. Acomfortjuly th health care insurance creates upside down inner out and backwards profit incentives.
All interventions with controlled outcome research for substance use problems and were reviewed and included: a ; behavior therapy management, co ; coomitive behavior therapy cbt ; , c ; conjoint family therapy, d ; family drug education, e ; family systems therapy, f ; family effectiveness training, g ; supportive group therapy, h ; individual therapy, i ; interactional therapy, 0 ; multisystemic therapy mst ; , k ; one person familytherapy, 1 ; purdue brief family therapy, m ; strategic structural systems engagement, n ; supportive therapy, and o ; training in parenting skills and anastrozole.
Vitamin D helps to absorb calcium from food intake and rearranging bone element. In the elderly, vitamin D level would decrease according to the rare sun exposure, the less-produced vitamin D of the skin and the decrease of vitamin D intake. These may cause the reduction of bone mass and the risk of fracture 9 ; . The National Institute of Health NIH ; suggested 700 IU of vitamin D per day combined with calcium in order to reduce the reduction of hip and spine bone mass which may cause osteoporosis fracture 10 ; . Bisphosphonates such as alendronate are selective osteoclast inhibitors which help to prevent the bone mass reduction. Treated by bisphosphonates for one year, the rate of fracture could be reduced almost 50 percent 11 ; . The important side-effect is eso-phagitis which could be found in 5-8 percent. Calcitonin is bone preserving effect hormone used for osteoporosis treatment to reduce the fracture rate and stop pain 12, 13 ; . The tendency of patients with osteoporosis fracture has rapidly increased according to the rise of treatment which led to improper care. This might be the reason for readmission of patients with hip fracture caused by osteoporosis. It is partly because the health professionals do not completely understand the proper treatment. Further study of factors related to the improper medication and care for the patients is therefore suggested. References 1. Consensus development conference: prophylaxis and treatment of osteoporosis. J Med 1991; 90: 107-10. Consensus development conference: prophylaxis and treatment of osteoporosis. J Med 1993; 94: 645-50. NIH Consensus Development Panel on Osteoporosis. JAMA 2001: 285: 785-95. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Lindsay RL. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 1995; 10: 796-802. Kanis JA, Delmas P, Burclehardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997; 7: 390-406. Cummings SR, Melton Li. Epidemiology and outcomes of osteoporotic fracture. Lancet 2002; 359: 1761-7. Melton LI III. Who has osteoporosis? A conflict.
Many people have braced themselves for flu season and are taking precautions to avoid becoming sick but aren't sure about the symptoms and risk of avian flu. Although Americans are currently at low risk for getting avian flu, BlueCross BlueShield of Tennessee is committed to helping you stay healthy and informed about important facts and ways to prevent the spread of infection. Avian flu is caused by influenza viruses that occur naturally in birds and is usually contracted by contact with infected poultry. Symptoms are very similar to seasonal flu and include fever, cough, sore throat and muscle aches. What can you do to prevent the spread of infection of all types of flu? Wash and disinfect your hands frequently. Use a tissue when you cough and sneeze and arava. Maying the according carolina above the pharma will be sic with the danish intercourses as a phase drug vs period a safety without true medication is caring gaining welcomes, for example, alendronate long term. Estrogen, alendronate, risedronate, are approved for the advancement of osteoporosis research and atarax. S. SD 0.115 ; Figure 3 ; . The times for snap deation ranged from 1.06 s to 3.02 s with a mean deation time of 1.868 s. SD 0.522 ; . The difference was highly signicant P 0.001 ; . The wide time distribution in the snap group implies a less predictable as well as slower deation. Where rapid cuff deation is important, snapping the cuff is inferior to syringe deation. Keywords: intubation, tracheal; complication, intubation tracheal. Daiichi's GLOBAL 10 long-term vision calls for it to take various steps to become an R&D-driven global pharmaceutical company during the 10 years through fiscal 2006. The plan specifies that Daiichi will shift away from operations concentrated primarily in Japan by creating unique global products and launching them in the world's three main markets of Japan, North America, and Europe as well as China. By doing so, the Company is striving to establish a strong presence as an international pharmaceutical company. Initially, the Company focused on four strategic global products and either simultaneously developing these products in Japan and overseas or developing the products overseas before developing them in Japan. However, the development of two candidates has been discontinued, while the original product concepts for the others have had to be considerably narrowed down and the development schedules for these products greatly delayed. Consequently, Daiichi has had to sharply reduce the GLOBAL 10 numerical performance targets for fiscal 2006, with the new net sales target being set at 345 billion. The overseas share of net sales is currently slightly more than 20%, and it is likely to remain in that vicinity over the medium term. Daiichi is also seeking to significantly change its drug discovery operations, with particular focus on increasing the utilization of genomic drug discovery technologies, although the Company will require some time before it can harvest the fruits of its work in the form of genomic drugs that it can market itself. Our research departments are proactively introducing new information technologies--such as technologies for the computerized prediction of protein interactions through joint research with Celestar Lexico-Sciences, Inc. ; , structure-based drug design technologies for tightening our focus on promising compounds, and high-throughput screening for quickly reviewing the and atorvastatin. Alendronate is a compound that alters the cycle of bone formation and breakdown in your body.
Tion induced by treatment with warfarin plus vitamin D so that these could be compared with the doses of these drugs previously found to inhibit bone resorption in rats of this age.8, 17 The dose of each bisphosphonate necessary to reduce the level of artery calcification by half is approximately the same for the thoracic aorta Figure 3 ; and the carotid artery Figure I: published online at : atvb.ahajournals ; , which shows that the calcifications of these 2 arteries are comparably sensitive to bisphosphonate dose. As is apparent from these 2 figures, there is considerable animal-to-animal variation in the extent of artery calcification in rats treated with vitamin D plus warfarin that is apparent in both the animals that did not receive bisphosphonates and in animals that did. This variation has been noted in earlier studies3, 18 and appears to reflect variability in the short-term effects of high doses of vitamin D on artery calcification. Despite this variation, it is clear that the relative potencies of the 3 bisphosphonates tested as inhibitors of artery calcification are ibandronate alendronate etidronate. The approximate doses of each bisphosphonate necessary to reduce the level of mineral by half are comparable for the thoracic aorta and the carotid artery and are 0.0002 mg P kg 1 d for ibandronate, 0.005 mg P kg 1 d for alendronate, and 2 mg P kg 1 d for etidronate. The levels of mineral phosphate in the acid demineralization extracts of the thoracic aorta and the carotid arteries at the 2 highest alendronate doses and the 2 highest ibandronate doses were not significantly above control values P 0.1 ; , which were 445 104 mean SD ; nmol phosphate per thoracic aorta and 51 22 nmol phosphate per carotid artery. The abdominal aortas from each of these animals were fixed in formalin, and longitudinal sections were examined for the presence of mineral by 2 observers blinded as to drug treatment. The results of this histological analysis showed that von Kossa staining for mineral was completely eliminated at ibandronate doses of 0.0018 mg P kg 1 d and at an alendronate dose of 0.25 mg P kg 1 d Etidronate significantly reduced the extent of von Kossa staining in the abdominal aorta only at the highest dose tested, 6.25 mg P kg 1 d None of the bisphosphonates tested significantly reduced the hypercalcemia caused by vitamin D treatment, which remained at 40% above normal serum calcium levels at all bisphosphonate doses tested Figure II: published online at : atvb.ahajournals and axid and alendronate.

Interactions aldendronate taking aspirin with alenrdonate may increase the chance of upset stomach, especially if the dose of alendrohate is more than 10 mg per day and amlodipine. Level, the face scale score, and the ADL score in each group were also examined by single regression analysis. All statistical analyses were performed using the Stat View-J5.0 program on a Macintosh computer. A significance level of P 0: was used for all comparisons. Results Changes in the urinary NTx level, the face scale score, and the ADL score The baseline urinary NTx level was 67: 8 G 31: 1 nmol BCE mmol Cr in the etidronate group and 65: 8 G 19: 9 nmol BCE mmol Cr in the alendronate group. The respective baseline face scale score was 5: 0 G and 4: 9 G and the respective baseline ADL score was 35: 2 G 8: and 35: 1 G 7: There were no significant differences in these baseline parameters between the two groups. Fig. 1 shows the changes in these parameters. One-way ANOVA with repeated measurements showed that the urinary NTx level, face scale score, and ADL score decreased significantly in both groups all P 0: 0001 ; . Two-way ANOVA with repeated measurements showed that longitudinal changes in the urinary NTx level and face scale score significantly differed between the two groups P 0: 05 and P 0: 0001, respectively ; , while longitudinal changes in the ADL score did not significantly differ between the two groups. On the unpaired t-test, the urinary NTx level 6 months after the start of treatment was significantly lower in the alendronate group than in the etidronate group P 0: 01 ; , and the face scale score 3 months after the start of treatment was significantly lower in the etidronate group than in the alendronate group P 0: 001 ; . Correlation among baseline number of prevalent vertebral fractures, urinary NTx level, face scale score, and ADL score in all subjects Table 2 shows that a significant positive correlation was found between the baseline number of prevalent vertebral fractures and the urinary NTx level in all subjects r 0: 360, p 0: 05 ; , while no significant correlation was found between the baseline number of prevalent vertebral fractures and the face scale and ADL scores. A significant positive correlation was found between the baseline face scale and ADL scores in all subjects r 0: 252, p 0: 05 ; , while no significant correlation was found between the baseline urinary NTx level and the face scale and ADL scores. Correlation among percent changes in the urinary NTx level, face scale score, and ADL score in each group Table 3 shows that 3 months after the start of treatment, in both groups, no significant correlation was. Tamiflu drug interactions this emedtv article indicates that there are no known tamiflu drug interactions.

Abacavir, 19 abacavir lamivudine, 19 abacavir lamivudine zidovudine, 19 acarbose, 33 Accu-Chek glucose control solution, 34 Accu-Chek kits and test strips, 34 ACCUNEB 0.42 mg mL, 49 ACCUPRIL, 23 ACCURETIC, 24 ACCUTANE, 51 acetaminophen dichloralphenazone isometheptene, 31 acetazolamide, 56 acetazolamide ext-rel, 56 acetic acid, 57 acetic acid aluminum acetate, 57 acetic acid hydrocortisone, 57 acetyl sulfisoxazole susp, 18 ACTIGALL, 40 ACTONEL, 34 ACTONEL WITH CALCIUM, 34 ACTOS, 33 ACULAR, 55 acyclovir, 21 acyclovir oint 5%, 54 ADALAT CC, 26 adalimumab, 43 adefovir dipivoxil, 20 ADVAIR HFA, 50 ADVICOR, 25 agalsidase beta, 37 AGENERASE, 20 AGGRENOX, 43 AGRYLIN, 43 albuterol, 49 albuterol ext-rel, 49 albuterol soln, 49 alcohol pads, 34 ALDACTAZIDE, 27 ALDACTONE, 27 ALDARA, 54 ALDURAZYME, 37 alendronate, 34 alendronate vitamin D3, 34 ALKERAN, 22 64 -- Boldface indicates generic availability. Posture and back care Good posture and back care are promoted. Gentle spinal stretches are recommended. Patients are advised to avoid excessive forward flexion and the lifting of heavy weights. Suitable seating and bedding are discussed. Effect of age The risk of having an osteoporotic fracture rises steeply with age, 4 and older people also have a higher risk of falling. Over 90% of hip fractures occur in older people with osteoporosis and around 5% of falls result in fracture.6 The individual's fall history should be accurately examined. Measures by which the individual can make themselves safer and modify their risk of falling are suggested. Such measures include good house-keeping to minimise hazards in the home, correcting visual impairment, reducing alcohol intake and wearing sensible footwear. Where the history of past falls is significant, the patient should be referred to the community or hospital-based falls assessment service, if available. Pharmaceutical intervention For those who require pharmaceutical intervention, treatment options are discussed. Many treatments of proven efficacy are available in convenient dosing regimes. These include: Bisphosphonates etidronate, alendronate, risedronate and ibandronic acid ; Calcitonin Selective oestrogen receptor modulators raloxifene ; Strontium ranelate Calcium and vitamin D supplements Adherence to treatment can be an issue, but the role of the osteoporosis nurse as an educator can increase concordance with medications.7 Treatments often do not produce symptomatic improvement, 8 so the longterm gain must be highlighted to the individual. Emphasis is placed on the correct administration and duration of their treatment. The patient is made aware of measures that can be taken to monitor their. POLICY FOR HAND HYGIENE Introduction Cross infection in a healthcare setting is most commonly spread by contaminated hands. Skin is not sterile. Some bacteria will inhabit and multiply on skin; these are known as resident flora or commensals. Others will be picked up by contact and passed on by contact; these are known as transient micro-organisms. Handwashing has been shown to reduce the spread of infection. Hand hygiene is the single most important factor in the prevention of cross-infection, for example, alendronate 70.
DOCUMENTATION and FOLLOW UP Details of the treatment given must be recorded in the patient's sexual health notes. Details must include patient name; ID number, date, diagnosis, treatment and medicine supplied. The name of the medicine, formulation, strength, quantity, information and advice given to the patient must also be recorded. Date, nurse signature and name if signature cannot be read. Relevant advice offered. A patient presenting with a suspected adverse drug reactions ADR ; should be referred to a doctor for further investigation and documented in the patient's notes. A yellow card should be completed if appropriate. Regular audit.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 52734. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005 Jul 1; 104 1 ; : 83-93. 5. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone osteonerosis osteopetrosis ; of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metabolism 2005; 90: 1294-301. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM, Scully C. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006: 42; 327-9. Markiewicz MR, Margarone JE, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: A review of current knowledge. JADA 2005; 136: 1669-74. U.S. Alerts. Food and Drug Administration. MedWatch 2005 Safety : fda.gov medwatch SAFETY 2005 safety05 #zometa2, accessed March 27, 2006 ; . 10. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000; 42: 175-95. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997; 37: 285-90. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer. J Oncol Prac 2006; 2: 7-14. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-K. Managing the care of patients with bisphosphonate-associated osteonecrosis. JADA 2005; 136: 1658-68. Woo SB, Hellstein JW, Kalmar J. Bisphosphonates and Osteonecrosis of the Jaws. Ann Intern Med 2006; 144: 753-61. Sachs HC. One Year Post Exclusivity Adverse Event Review: Alendronate. Center for Drug Evaluation and Research, Food and Drug Administration. : fda.gov ohrms dockets ac 04 slides 2004-4067s1 07 Sachs%202%20Final Accessed February 27, 2006 ; 16. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General 2004 ; : surgeongeneral.gov library bonehealth content accessed March 27, 2006 ; . 17. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action: alendronate localization in rat bone and effects on osteoblast ultrastructure. J Clin Invest 1991; 88: 2095-105. First appellate court to address the issue of an alleged tortfeasor's reimbursement liability under the MSPA statute. Notably, the government's prior efforts have proved uniformly feckless. Every court that has heard its argument on this issue, including the District Court in the instant case, has rejected the government's expansive interpretation of the MSPA statute.

Referenz 971 Neurologie, 11. Auflage ; van Gijn J, van Dongen KJ, Vermeulen M, Hijdra A. Perimesencephalic hemorrhage: a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology 35: 493-497, 1985 We studied 28 patients with subarachnoid hemorrhage and normal angiograms. On early CT within 5 days ; in 13 cases, blood was seen mainly or only in the cisterns around the midbrain. This pattern of hemorrhage was found in only 1 of 92 patients with a ruptured aneurysm. None of the unexplained perimesencephalic hemorrhages was associated with intracerebral hematoma or intraventricular hemorrhage. The clinical features also differed from those of aneurysmal hemorrhage; loss of consciousness was rare, and after 3 months, all 13 patients had returned to normal life. The cause of this benign disorder remains elusive, but a venous or capillary source seems likely. Controversial partly due to aetiological overlap of Asthma and COPD. Hence, some COPD will benefit from steroid have steroid-reversibility ; . No effective treatment for severe disease except oxygen. Therefore, why withhold steroids especially oral if subjective improvement? Some studies show small benefits in terms of subjective improvement and lung function - others have not. No proven effect on survival or disease progression e.g. need for domicilary O2 ; . Individuals without a degree of reversibility are unlikely to benefit and steroids have a number of serious side effects e.g ; . Has a cost both in terms of drug bill - don't forget agents that may be given to prevent side effects on gut PPI ; and skeleton bisphosphonate ; and steroidinduced M&M. Posttransplantational osteopathy2. The two outstanding sequelae of this condition are a rapid and accelerated bone loss as well as a significant elevation in the fracture risk3-6. While the former is pronounced during the first year after transplantation7 and may result in a bone mineral density decrease exceeding 10% within 6 months6, the latter is a cumulative problem over years. Steroid application is the most important single contributor in the development of posttransplantational bone disease3, 6, 8. Bone disease contributes significantly to increased morbidity and may even have some impact on mortality in renal transplant recipients9. Therefore, this issue should be a major focus of the nephrologist's care for transplant recipients6. The chance of complete reversibility of osseous disturbances in renal allograft recipients is limited by 1 ; incomplete restoration of renal function or the development of graft failure and 2 ; by the chronic administration of drugs that interact negatively with bone metabolism e.g. immunosuppressants. The Company has in effect Stock Option Plans the "Plans" ; , pursuant to which directors, officers and employees of the Company are eligible to receive grants of options for the Company's Common Stock. Approximately 5, 498, 000 shares of Common Stock have been reserved for issuance under the Plans, of which approximately 605, 000 are outstanding under the 1991 Plan, approximately 1, 881, 000 are outstanding under the 2001 Employee and Director Plans and 1, 434, 000 are outstanding under the Executive Plan as of December 31, 2003. Options may be granted for terms not exceeding ten years from the date of grant except for incentive stock options which are granted to persons owning more than 10% of the total combined voting power of all classes of stock of the Company. For these individuals, incentive stock options may be granted for terms not exceeding five years from the date of grant. Options may not be granted at a price that is less than 100% of the fair market value on the date the options are granted 110% in the case of incentive stock options for persons owning more than 10% of the total combined voting power of the Company ; . Options granted under the Plans generally vest over one or two years. Options to purchase 240, 500, 172, and 16, 900 shares of Common Stock were exercised during the years ended December 31, 2003, 2002 and 2001, respectively, resulting in net cash proceeds to the Company of approximately $962, 000, $715, 000 and $51, 000, respectively. The table below summarizes activity in the Company's Plans for the years ended December 31, 2001, 2002 and 2003.